Latest News

Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

View Press Release

Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023

View Press Release

Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference

View Press Release

Latest Presentation

Investor Presentation

Upcoming Event

European Society for Medical Oncology Immuno-Oncology (ESMO I‑O) Annual Congress

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2022

Company Overview

Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions, including multiple sclerosis, that can be rapidly delivered to patients within days. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile Epstein-Barr virus (EBV) T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in addition to next-generation AlloCAR-Ts designed for best-in-class opportunities across a broad range of non-EBV-associated liquid and solid tumors. Atara is headquartered in Southern California.

Stock Snapshot

Investor & Media Contacts

Investor and Media Relations

Alex Chapman
Vice President, Corporate Communications & Investor Relations
T: (805) 456-4772

Jason Awe, Ph.D.
Senior Director, Corporate Communications & Investor Relations
T: (805) 217-2287

Transfer Agent

Computershare Trust Company, N.A.
P.O. Box 505000
Louisville, KY 40233
T: (781) 575-2879

Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.